Themis Medicare Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Themis Medicare için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.8%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

What Themis Medicare Limited's (NSE:THEMISMED) 42% Share Price Gain Is Not Telling You

Dec 27

Themis Medicare (NSE:THEMISMED) Has Announced That It Will Be Increasing Its Dividend To ₹5.00

Aug 28

Themis Medicare (NSE:THEMISMED) Is Increasing Its Dividend To ₹5.00

Aug 08

Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's

Jul 21

Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's

May 27

Is Now The Time To Put Themis Medicare (NSE:THEMISMED) On Your Watchlist?

May 12

Calculating The Fair Value Of Themis Medicare Limited (NSE:THEMISMED)

Nov 09

Is Now The Time To Put Themis Medicare (NSE:THEMISMED) On Your Watchlist?

Oct 26

Increases to Themis Medicare Limited's (NSE:THEMISMED) CEO Compensation Might Cool off for now

Sep 11

Themis Medicare (NSE:THEMISMED) Is Increasing Its Dividend To ₹4.30

Aug 16

Do Themis Medicare's (NSE:THEMISMED) Earnings Warrant Your Attention?

Jul 09

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Themis Medicare yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NSEI:THEMISMED - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2024	4,203	530	187	384	N/A
6/30/2024	4,081	500	N/A	N/A	N/A
3/31/2024	3,818	435	37	221	N/A
12/31/2023	3,640	453	N/A	N/A	N/A
9/30/2023	3,703	512	-89	179	N/A
6/30/2023	3,565	577	N/A	N/A	N/A
3/31/2023	3,543	569	-127	161	N/A
12/31/2022	3,540	584	N/A	N/A	N/A
9/30/2022	3,602	576	-72	180	N/A
6/30/2022	3,765	591	N/A	N/A	N/A
3/31/2022	3,946	729	138	344	N/A
12/31/2021	3,766	710	N/A	N/A	N/A
9/30/2021	3,472	703	395	570	N/A
6/30/2021	2,947	591	N/A	N/A	N/A
3/31/2021	2,307	357	389	570	N/A
12/31/2020	2,151	349	N/A	N/A	N/A
9/30/2020	2,033	338	131	263	N/A
6/30/2020	1,987	274	N/A	N/A	N/A
3/31/2020	2,016	248	-55	3	N/A
12/31/2019	1,911	61	N/A	N/A	N/A
9/30/2019	1,855	-45	99	124	N/A
6/30/2019	1,846	-64	N/A	N/A	N/A
3/31/2019	1,838	-107	53	109	N/A
12/31/2018	2,002	54	N/A	N/A	N/A
9/30/2018	2,022	78	N/A	N/A	N/A
6/30/2018	2,063	101	N/A	N/A	N/A
3/31/2018	2,095	113	N/A	79	N/A
12/31/2017	2,354	105	N/A	N/A	N/A
9/30/2017	2,399	143	N/A	N/A	N/A
6/30/2017	2,323	142	N/A	N/A	N/A
3/31/2017	2,167	160	N/A	-15	N/A
12/31/2016	2,438	211	N/A	N/A	N/A
9/30/2016	2,368	212	N/A	N/A	N/A
6/30/2016	2,404	208	N/A	N/A	N/A
3/31/2016	2,324	163	N/A	258	N/A
12/31/2015	2,287	155	N/A	N/A	N/A
9/30/2015	2,227	142	N/A	N/A	N/A
6/30/2015	2,022	71	N/A	N/A	N/A
3/31/2015	2,019	62	N/A	191	N/A
3/31/2014	1,951	27	N/A	83	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: THEMISMED 'un tahmini kazanç büyümesinin tasarruf oranının ( 6.7% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: THEMISMED 'un kazançlarının Indian pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: THEMISMED şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: THEMISMED şirketinin gelirinin Indian pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: THEMISMED şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: THEMISMED 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Themis Medicare Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Themis Medicare Limited (BSE:530199) agreed to acquire remaining 76.8% stake in Gujarat Themis Biosyn Limited (BSE:506879) for INR 26.9 billion.

Second quarter 2025 earnings released: EPS: ₹1.55 (vs ₹1.23 in 2Q 2024)

Themis Medicare Limited to Report Q2, 2025 Results on Oct 25, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 16%

Themis Medicare Limited Announces Executive Changes

First quarter 2025 earnings released: EPS: ₹2.68 (vs ₹1.98 in 1Q 2024)

Themis Medicare Limited Approves Dividend for the Financial Year Ended 31 March 2024

Themis Medicare Limited to Report Q4, 2024 Results on Jul 26, 2024

Upcoming dividend of ₹0.50 per share

Full year 2024 earnings released: EPS: ₹4.73 (vs ₹6.18 in FY 2023)

Themis Medicare Limited to Report Q1, 2025 Results on Aug 14, 2024

Themis Medicare Limited, Annual General Meeting, Jul 22, 2024

Full year 2024 earnings released: EPS: ₹4.73 (vs ₹6.18 in FY 2023)

Themis Medicare Limited Recommends Dividend for Financial Year Ended March 31, 2024, Payable on or after July 22, 2024

Themis Medicare Limited to Report Q4, 2024 Results on May 14, 2024

Investor sentiment improves as stock rises 19%

Third quarter 2024 earnings released: EPS: ₹0.80 (vs ₹1.45 in 3Q 2023)

What Themis Medicare Limited's (NSE:THEMISMED) 42% Share Price Gain Is Not Telling You

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 16%

Themis Medicare (NSE:THEMISMED) Takes On Some Risk With Its Use Of Debt

Investor sentiment improves as stock rises 16%

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ₹12.30 (vs ₹1.93 in 2Q 2023)

New minor risk - Market cap size

Investor sentiment deteriorates as stock falls 90%

High number of new directors

Themis Medicare Limited Appoints Reena Patel as Alternate Non-Executive Non- Non-Independent Director to Dr. Adam Demeter, Effective September 11, 2023

Upcoming dividend of ₹5.00 per share at 0.3% yield

Themis Medicare Limited to Report First Half, 2024 Results on Nov 14, 2023

Themis Medicare (NSE:THEMISMED) Has Affirmed Its Dividend Of ₹5.00

First quarter 2024 earnings released: EPS: ₹19.77 (vs ₹18.92 in 1Q 2023)

Themis Medicare Limited to Report Q1, 2024 Results on Aug 10, 2023

Themis Medicare's (NSE:THEMISMED) Dividend Will Be ₹5.00

Themis Medicare Limited to Report Q1, 2024 Results on Aug 12, 2023

Themis Medicare's (NSE:THEMISMED) Dividend Will Be ₹5.00

We Think Themis Medicare (NSE:THEMISMED) Is Taking Some Risk With Its Debt

Themis Medicare (NSE:THEMISMED) Is Due To Pay A Dividend Of ₹5.00

Full year 2023 earnings released: EPS: ₹61.81 (vs ₹79.22 in FY 2022)

Themis Medicare Limited Recommends Dividend for Financial Year Ended 31 March 2023

Themis Medicare Limited to Report Q4, 2023 Results on May 13, 2023

Themis Medicare Announces DCGI Approval of Remifentanil Hydrochloride 1mg/2mg for Injection for Import and Marketing

Third quarter 2023 earnings released: EPS: ₹14.47 (vs ₹13.54 in 3Q 2022)

Themis Medicare Limited to Report Q3, 2023 Results on Feb 03, 2023

Insider recently sold ₹1.1m worth of stock

Themis Medicare Ltd. Launches Lenzetto Global Brand of Estradiol Novel Drug Delivery System

Themis Medicare Ltd. Launches Lenzetto Global Brand of Estradiol Novel Drug Delivery System

Themis Medicare (NSE:THEMISMED) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: ₹19.33 (vs ₹20.95 in 2Q 2022)

Themis Medicare Limited to Report Q2, 2023 Results on Nov 07, 2022

Less than half of directors are independent

Themis Medicare Limited Informs the Second Term of Office of Mr. Hoshang Sinor as Independent Director, Come to End

Investor sentiment improved over the past week

Themis Medicare Limited Announces Resignation of Lajos Kovacs as Board of Directors

Upcoming dividend of ₹5.00 per share

Themis Medicare (NSE:THEMISMED) Has Announced That It Will Be Increasing Its Dividend To ₹5.00

Themis Medicare (NSE:THEMISMED) Is Increasing Its Dividend To ₹5.00

First quarter 2023 earnings released: EPS: ₹37.84 (vs ₹33.93 in 1Q 2022)

Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's

Themis Medicare Limited to Report Q1, 2023 Results on Jul 28, 2022

Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's

Themis Medicare Limited Recommends Dividend for Financial Year Ended March 31, 2022

Full year 2022 earnings released: EPS: ₹79.22 (vs ₹38.86 in FY 2021)

Themis Medicare Limited, Annual General Meeting, Sep 19, 2022

Themis Medicare Limited Announces Approval for Drug VIRALEX by the Drug Controller General of India

Is Now The Time To Put Themis Medicare (NSE:THEMISMED) On Your Watchlist?

Now 21% undervalued after recent price drop

Themis Medicare Limited Announces Resignation of Jayshree Dinesh Patel as Whole-Time Director

Themis Medicare Limited Announces Approval of Its Antiviral Drug VIRALEX by the Drug Controller General of India

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Themis Medicare Limited Announces Retirement of Jayshree D Patel, Whole Time Director

Second quarter 2022 earnings released: EPS ₹20.95 (vs ₹8.85 in 2Q 2021)